Systemic adverse events after bevacizumab.
Roth
Daniel B
DB
King
Alex
A
Weiss
Meredith
M
Klein
Daniel
D
D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007267:Injections; D008297:Male; D009203:Myocardial Infarction / Q000139:chemically induced; D012164:Retinal Diseases / Q000188:drug therapy; D012189:Retrospective Studies; D020521:Stroke / Q000139:chemically induced; D011795:Surveys and Questionnaires; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab